Nanohale, a German firm developing new formulations of protein and peptide therapeutics, has acquired the R&D and contract development and manufacturing services assets of Scil Technology, bringing them into a new wholly owned subsidiary called Formycon.
Scil Technology itself will remain as an independent company with rights to the tissue regeneration projects outlicensed to Medtronic (the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?